A citation-based method for searching scientific literature

N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote, T Baert, I Belaroussi, A Dashora, S Olbrecht, F Planchamp, D Querleu. Ann Oncol 2019
Times Cited: 207



Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédéric Selle, Jalid Sehouli, Domenica Lorusso, Eva M Guerra Alía, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre-Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Eric Pujade-Lauraine, Philipp Harter. N Engl J Med 2019
Times Cited: 304




List of shared articles



Times cited

Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network.
Caterina Fumagalli, Elena Guerini-Rocco, Fiamma Buttitta, Pierluigi Iapicca, Wenqi You, Michela Mauri, Lara Felicioni, Giancarlo Troncone, Umberto Malapelle, Aldo Scarpa,[...]. J Clin Pathol 2021
0

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Chongzhen Guo, Chengda Yan, Lianyue Qu, Rongrong Du, Jianyang Lin. Arch Gynecol Obstet 2021
1

How to sequence treatment in relapsed ovarian cancer.
Sandro Pignata, Sabrina Chiara Cecere. Future Oncol 2021
1

Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Céline Callens, Dominique Vaur, Isabelle Soubeyran, Etienne Rouleau, Pierre-Alexandre Just, Erell Guillerm, Lisa Golmard, Nicolas Goardon, Nicolas Sevenet, Odile Cabaret,[...]. J Natl Cancer Inst 2021
2

HIPEC: Turning up the heat on ovarian cancer.
Rhonda Farrell, Michael Burling. Aust N Z J Obstet Gynaecol 2021
2

SEOM clinical guideline in ovarian cancer (2020).
A Redondo, E Guerra, L Manso, C Martin-Lorente, J Martinez-Garcia, J A Perez-Fidalgo, M Q Varela, M J Rubio, M P Barretina-Ginesta, A Gonzalez-Martin. Clin Transl Oncol 2021
1

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
3

Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Ionut-Gabriel Funingana, Marika A V Reinius, Angelica Petrillo, Joo Ern Ang, James D Brenton. Semin Cancer Biol 2021
1

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
4

First line ovarian cancer treatment: Scanning the horizon.
D Lorusso, G Daniele. Crit Rev Oncol Hematol 2021
0

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander,[...]. Lancet Oncol 2021
18

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso. Cancers (Basel) 2021
2

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma.
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song. Cancers (Basel) 2021
0

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021
3

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin. J Ovarian Res 2021
0

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Laura Ardighieri, Francesco Missale, Mattia Bugatti, Luisa Benerini Gatta, Irene Pezzali, Matilde Monti, Stefano Gottardi, Laura Zanotti, Eliana Bignotti, Antonella Ravaggi,[...]. Front Immunol 2021
1

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A Ledermann, Ursula A Matulonis, Amit M Oza, Ilan Bruchim, Tomasz Huzarski,[...]. Eur J Cancer 2021
0

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
Alexandre De Nonneville, Christophe Zemmour, Sophie Frank, Florence Joly, Isabelle Ray-Coquard, Hèlène Costaz, Jean-Marc Classe, Anne Floquet, Thibault De la Motte Rouge, Pierre-Emmanuel Colombo,[...]. Gynecol Oncol 2021
0

The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers.
Silvana Talisa Wijaya, Natalie Yl Ngoi, David Sp Tan. Best Pract Res Clin Obstet Gynaecol 2021
0